Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;43(6):1066-1074.
doi: 10.1007/s11596-023-2797-3. Epub 2023 Oct 14.

Clinical Characteristics, Diagnosis, and Therapeutics of COVID-19: A Review

Affiliations
Review

Clinical Characteristics, Diagnosis, and Therapeutics of COVID-19: A Review

Na-Na Xie et al. Curr Med Sci. 2023 Dec.

Abstract

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that suddenly emerged at the end of December 2019 and caused coronavirus disease 2019 (COVID-19) continues to afflict humanity, not only seriously affecting healthcare systems but also leading to global social and economic imbalances. As of August 2022, there were approximately 580 million confirmed cases of COVID-19 and approximately 6.4 million confirmed deaths due to this disease. The data are sufficient to highlight the seriousness of SARS-CoV-2 infection. Although most patients with COVID-19 present primarily with respiratory symptoms, an increasing number of extrapulmonary systemic symptoms and manifestations have been associated with COVID-19. Since the outbreak of COVID-19, much has been learned about the disease and its causative agent. Therefore, great effort has been aimed at developing treatments and drug interventions to treat and reduce the incidence of COVID-19. In this narrative review, we provide a brief overview of the epidemiology, mechanisms, clinical manifestations, diagnosis, and therapeutics of COVID-19.

Keywords: clinical manifestations; coronavirus disease 2019; diagnosis; mechanism; severe acute respiratory syndrome coronavirus 2; therapeutics.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol, 2020,5(4):536–544 - DOI
    1. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses, 2020,12(2):135 - PubMed - PMC - DOI
    1. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA, 2020,324(8):782–793 - PubMed - DOI
    1. Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet, 2020,395(10223):470–473 - PubMed - PMC - DOI
    1. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020,395(10223):514–523 - PubMed - PMC - DOI

LinkOut - more resources